|
Age at LTX, median (IQR)
|
45 (34–51)
|
50 (44.5–53.5)
|
43 (33–50)
|
0.062
|
|
Male, n (%)
|
48 (38.7%)
|
7 (53.8%)
|
41 (36.9%)
|
0.247
|
|
LTX procedure, n (%)
| | | |
< 0.0001
|
|
Cadaveric single
|
67 (54.0%)
|
0 (0.0%)
|
67 (60.4%)
| |
|
Cadaveric bilateral
|
48 (38.7%)
|
12 (92.3%)
|
36 (32.4%)
| |
|
Living-donor
|
9 (7.3%)
|
1 (7.7%)
|
8 (7.2%)
| |
|
LTX indication category, n (%)
| | | |
N/A
|
|
Suppurative lung disease
|
13 (10.5%)
|
13 (100%)
| | |
|
Restrictive lung disease
|
30 (24.2%)
| |
30 (27.0%)
| |
|
Pulmonary vascular disease
|
27 (21.8%)
| |
27 (24.3%)
| |
|
Obstructive lung disease
|
51 (39.5%)
| |
51 (49.9%)
| |
|
Others
|
3 (2.4%)
| |
3 (2.7%)
| |
|
Chronic sinusitis, n (%)
|
19 (15.3%)
|
10 (76.9%)
|
9 (8.1%)
|
< 0.0001
|
|
Connective tissue disease, n (%)
|
14 (11.3%)
|
2 (15.4%)
|
12 (10.8%)
|
0.641
|
|
Gastroesophageal reflux disease, n (%)
|
10 (8.1%)
|
2 (15.4%)
|
8 (7.2%)
|
0.282
|
|
Diabetes
|
8 (6.5%)
|
0 (0.0%)
|
8 (7.2%)
|
0.999
|
|
Underweight (BMI < 18.5 kg/m2), n (%)
|
67 (54.0%)
|
6 (46.2%)
|
61 (55.0%)
|
0.571
|
|
History of Pseudomonas colonization, n (%)
|
13 (10.5%)
|
12 (92.3%)
|
1 (0.9%)
|
< 0.0001
|
|
History of NTM isolation, n (%)
|
5 (4.0%)
|
1 (7.7%)
|
4 (3.6%)
|
0.431
|
|
Ischemic time (min), median (IQR)
|
502 (431–666)
|
685 (635–734)
|
493 (429–643)
|
0.002
|
|
CMV mismatch, n (%)
|
21 (16.9%)
|
1 (8.3%)
|
20 (18%)
|
0.689
|
